Stryker Rejuvenate Recall
Stryker Rejuvenate Litigation in State and Federal courts
Stryker Orthopaedics Rejuvenate has ceased to recruit subjects for its longitudinal study on one of its two recently recalled hip implant models, but it has continued to try to resolve lawsuits filed by the ailing patients of both hip replacement stems.
Meanwhile, a major orthopedic medical journal has published a study that reaffirmed the corrosive potential of such devices. This began the Stryker Rejuvenate recall and the Stryker ABG II Recall.
The New Jersey-based medical technology corporation June 28, 2012, voluntarily issued a Stryker Rejuvenate recall and ABG II modular-neck hip stems recall and announced July 6, 2012, that it had “terminated global distribution of these products” based on data derived from “continued post-market surveillance.”
Stryker Rejuvenate Recall for Metal on Metal Parts
These were not all-metal devices. Nevertheless, the necks, for instance, were made of a “cobalt chrome alloy,” according to Stryker’s answer to lawsuits filed in state court in New Jersey. The metal parts posed certain adverse-reaction risks. Ultimately, as New Jersey’s multi-county litigation center quoted the manufacturer, “These risks include the potential for fretting and/or corrosion at or about the modular-neck junction, which may result in adverse local tissue reactions manifesting with pain and/or swelling. … Possible adverse outcomes allegedly include metallosis, necrosis and osteolysis.”
Studies on the Stryker Hip Rejuvenate Recall
The May 2013 edition of The Journal of Bone & Joint Surgery published research in accordance with the reported damage that plaintiffs in Stryker class action lawsuits have suffered.
“Corrosion at the modular neck-body junction in dual-tapered stems with a modular cobalt-chromium-alloy femoral neck can lead to release of metal ions and debris resulting in local soft-tissue destruction,” concluded researchers from Northwestern University and Indiana University medical schools and from Rush University Medical Center.
They evaluated the case studies on 12 new hips at multiple medical centers. “Adverse local tissue reaction should be considered as a potential cause for new-onset pain in patients with these components, and early revision should be considered given the potentially destructive nature of these reactions.
“A workup including serologic studies (erythrocyte sedimentation rate and C-reactive protein), serum metal levels, and MARS MRI can be helpful in establishing this diagnosis.”
This process is very painful, time consuming and expensive. The defectiveness of these products has lead (and will continue to lead) to additional surgeries, rehabilitation and more. This is where the Stryker lawsuit becomes imperative, as the people affected by these products deserve compensation.
Stryker asking Doctors to follow up closely after the Stryker Rejuvenate Recall
Some of the adverse-event reports were serious enough that Stryker stated in its patient follow-up guidance, “Stryker is suggesting that surgeons consider performing a clinical examination, such as blood work and cross sectional imaging, on all patients who received a Rejuvenate or ABG II modular-neck hip stem regardless of whether a patient is experiencing pain and/or swelling.”
Continuing to observe the performance of the Rejuvenate model, Stryker has been sponsoring a clinical trial since November 2010, for which data is scheduled to be collected through November 2022.
Trial researchers reported April 12 that the study had ceased recruiting subjects. The Stryker Rejuvenate patients “will be evaluated for freedom of hip revision at 5 years and clinical outcomes for up to 10 years after surgery,” according to a summary of the study made available by the U.S. National Institute of Health.
Stryker Rejuvenate Recall Sends Many Back for Revision Surgery
Many patients, especially those who have been injured by Stryker Rejuvenate have turned to their surgeons for help, an option Stryker has been recommending.
Some have taken the additional step of exercising their right to seek compensation.
Stryker has been defending itself from hip replacement failure litigation filed at the state and federal levels. The door is still open for injured patients to follow suit. And Stryker has been financially equipping for the formidable challenge.
Referring to the cost of dealing with product liability lawsuits on one hand and reimbursements for patient testing, treatment and revision surgeries on the other, Stryker estimated that “the probable loss to resolve this matter would be in the range of approximately $190 million to $390 million, before third-party insurance recoveries,” according to Stryker’s recently released annual report for 2012.
Claimants’ causes of action include:
- defects in design and in manufacture
- the failure to warn of increased risks of serious complications
Some lawsuits have sought compensation for impairment of marital relations that hip replacement injury and surgical revision have caused.
Stryker Rejuventate Recall Lawsuit Litigation has Started
Multi-county state-court litigation has been centralized in New Jersey, the home state of Stryker Orthopaedics, before Judge Brian R. Martinotti in Bergen County. The next status conference has been scheduled for June 18.
Meanwhile, federal multidistrict litigation was designated for oral arguments at a May 30 hearing in Louisville, Ky., where two plaintiffs motioned for the consolidation of certain actions to federal district court in Minnesota and to federal district court for the Northern District of Illinois.
Contact the Law Firms for Stryker Rejuvenate Recall and Lawsuit Eligibility!
Anyone who has suffered tissue damage and related injuries that may be traced to the Stryker Rejuvenate Recall or ABG II Recall may be entitled to compensation.
One way to determine all of the legal options, without charges and fees, is to seek a free consultation from one of the experienced trial litigation attorneys from our group.
Contact us today about the Stryker Hip Recall Lawsuit at:
Or fill out our form on this page to be contacted by us.